title: Biodistribution of 111In-labelled IgG and IgM in experimental infection.
abstract: Both the protein used and the conjugation method are factors which may be relevant for targeting infection with 111In-labelled proteins. In this study, human immunoglobulin G (IgG), conjugated to either DTPA or LiLo, and LiLo conjugated human immunoglobulin M (IgM) were evaluated. In rats with Staphylococcus aureus calf muscle infection, biodistribution was determined 6, 24 and 48 h after the injection of 111In-DTPA-IgG, 111InLiLo-IgG or 111In-LiLo-IgM. Absolute abscess uptake of 111In-LiLo-IgG was significantly higher than that of 111In-DTPA-IgG (P < 0.05). Since blood clearance of 111In-LiLo-IgG was initially significantly slower (P < 0.01), the higher abscess uptake did not result in higher abscess-to-background ratios. 111In-LiLo-IgG accumulated to a greater extent in the liver (P < 0.001). 111In-DTPA-IgG showed higher uptake in the kidneys and bone marrow (P < 0.001 and P < 0.01, respectively). Although decreasing over time, 111In-LiLo-IgM showed reasonable abscess uptake and rapid blood clearance, resulting in higher abscess-to-background ratios compared with 111In-LiLo-IgG (P < 0.01). However, liver and spleen uptake were three- to four-fold higher than that of 111In-LiLo-IgG (P < 0.001). Compared with DTPA-conjugation, chelation with LiLo has a minor influence on abscess targeting of 111In-labelled IgG. However, differences in blood clearance and organ uptake do occur. 111In-LiLo-IgM shows high relative accumulation in abscesses as well as high liver and spleen uptake. 111In-LiLo-IgM appears promising for imaging infection outside the trunk region.
authors.affiliation: Department of Nuclear Medicine, University Hospital Nijmegen, The Netherlands.
authors.forename: W J
authors.initials: WJ
authors.lastname: Oyen
authors.forename: O C
authors.initials: OC
authors.lastname: Boerman
authors.forename: R
authors.initials: R
authors.lastname: Subramanian
authors.forename: E B
authors.initials: EB
authors.lastname: Koenders
authors.forename: R A
authors.initials: RA
authors.lastname: Claessens
authors.forename: J W
authors.initials: JW
authors.lastname: van der Meer
authors.forename: F H
authors.initials: FH
authors.lastname: Corstens
mesh_terms: D000818:Animals; D002614:Chelating Agents / Q000493:pharmacokinetics; D004355:Drug Stability; D005069:Evaluation Studies as Topic; D006801:Humans; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007205:Indium Radioisotopes / Q000493:pharmacokinetics; D008297:Male; D004369:Pentetic Acid / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D011877:Radionuclide Imaging; D051381:Rats; D017208:Rats, Wistar; D013203:Staphylococcal Infections / Q000000981:diagnostic imaging* / Q000276:immunology / Q000378:metabolism; D014018:Tissue Distribution
chemical_list: D002614:Chelating Agents; C069971:DTPA-IgG complex; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007205:Indium Radioisotopes; C076593:1,3-bis(N-(N-(2-aminoethyl)-2-aminoethyl)-2-aminoacetamido)-2-(4-isothiocyanatobenzyl)propane-N,N,N',N'',N''',N'''',N''''',N'''''-octaaceticacid; D004369:Pentetic Acid